NTT
NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT DATA Corporation, NTT COMWARE Corporation, NTT Communications Corporation, NTT Ltd., Nippon Telegraph and Telephone East Corporation (Hereinafter, NTT East)) will begin a joint study with Denenchofufutaba Gakuen in order to develop smart campus solutions that will provide safety and security at schools. NTT Group implements technology of public safety solution that will draw on the proven implementation for the City of Las Vegas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005916/en/
1. Background
In recent years, there have been several crimes and incidents involving students in school facilities, and resulting in requests to improve safety measures in addition to crime prevention activities by national and local governments. Furthermore, with the introduction of new educational guidelines, the workload of teachers is increasing, and there is a growing need for efficient and effective safety measures according to those in the field of school education. In order to respond to such needs, NTT Group aims to develop smart campus solutions that contribute to the strengthening of school safety with Denenchofufutaba Gakuen. This will leverage ICT solutions based on the system integration and application development capabilities of the public safety experience gained by providing smart city solutions*1 to the City of Las Vegas, in the United States.
2. Outline of the Joint Study
This joint study aims to build a data aggregation infrastructure that enables situational awareness of danger in the school by using high-resolution video cameras, audio sensors and IoT devices, analyze and predict dangerous events for students, and verify the solutions that contribute to strengthening school safety measures.
(1) Solution Features
The first step starts with the implementation of a system to monitor and report the traffic of vehicles and establish a system to ensure the safety of students when they move between school buildings. Through the operation of this system, the future needs of safety measures and solutions are studied to create new solutions that enables situation analysis uses AI, machine learning technology and 5G related technology.
The data aggregation infrastructure is built on the architecture of NTT's innovative Cognitive Foundation ®*2 , which enables the remote creation, management, and operation of ICT resources, from devices and networks to the cloud.
(2) Points to be verified through Joint Study
Based on the operation of the above solution, the following will be developed with Denenchofufutaba Gakuen.
1) Identification of safety measures in school facilities
2) Identification of technical issues in system integration and operations
3) Creation of solutions using ICT technology
4) Feasibility study as a repeatable campus solution
(3) Period and location of implementation
- Period: Start from February 2020
- Location: Denenchofufutaba Gakuen Campus
(4) Role of each company
NTT Group |
NTT |
Overall supervision and coordination among group companies |
NTT DATA |
Joint planning, environment set-up and solution implementation
|
|
NTT COMWARE |
Multi-Orchestrator delivery and technical support |
|
NTT Communications |
Provision of cloud environment and technical support, Support for Multi-Orchestrator installation |
|
NTT Ltd |
Support for deployment and technical support of smart city solutions as per the City of Las Vegas implementation |
|
NTT East |
Provision of access network, support for network related technologies |
|
Denenchofu Futaba Gakuen |
Joint study planning support (Providing issues and needs) |
|
3. For the Future
In the future, with the learning from this joint study with Denenchofufutaba Gakuen, NTT Group will contribute to the enhancement of school safety by creating new smart campus solutions in the second quarter of 2020.
*1 (press release) About the smart city solutions available in Las Vegas, USA
https://www.ntt.co.jp/news2018/1812/181208a.html
*2 "Cognitive Foundation" is a registered trademark of Nippon Telegraph and Telephone Corporation in Japan.
About NTT
NTT is a Global Technology and Business Solutions Provider. We help clients accelerate growth and innovate new digital business models of the future. We provide business consulting and technology services for global networks, cybersecurity, managed IT and applications, workplace, datacenter and cloud services all supported by our deep industry expertise and innovation.
As a top five Global IT Services provider, our globally diverse and inclusive workforce supports clients in 80+ countries and regions. This includes 85% of the Fortune Global 100 companies and thousands of other clients and communities. With a 120-year heritage of service, innovation and social responsibility, we always advocate and act for our clients and a sustainable future. For more information on NTT, visit www.global.ntt/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005916/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom